The focus of this study is childhood asthma exacerbations, which are common, potentially life-threatening and are a considerable financial burden to healthcare systems. Annually in the UK 150,000 children see their family doctor for an asthma exacerbation and 25,000 are hospitalised.  One third of the £1 billion NHS budget for asthma is spent on provision for unscheduled care of which about one half is for childhood exacerbations. Exacerbations are relatively infrequent and short-lived but their importance to patients is emphasised in the Global Initiative for Asthma whose major goals include “to prevent asthma exacerbations”. 

Previous studies undertaken that looked at Fractional exhaled Nitric Oxide (FeNo) as a biomarker, suggest that its use to guide asthma treatment could help reduce the number of children with an asthma exacerbation.

This study compares asthma treatment guided by “FeNO and sypmtoms” versus asthma treatment guided by "symptoms only" (i.e. standard care). In children with asthma.   FeNO and symptoms, or symptoms alone, are assessed every three months and are used to guide asthma treatment for the next three month period.  The primary outcome is asthma attacks over a 12 month period.  

This randomised multi-centre study, is funded by the NIHR EME Programme, recruited children and young people aged 6-16 years with asthma who have had an asthma attack treated with steroid tablets in the past year.   The twelve month follow-up is almost complete and we hope to report results from the study in 2021.  

The primary outcome is asthma exacerbation (attack) which will be assessed at the 3, 6, 9 and 12 month follow-up visits, and confirmed with data held in medical records. 

RAACENO is led by Professor Steve Turner based at the University of Aberdeen.

For more information please see the RAACENO website 


Jessica Wood;

Victoria Bell;


Data Collection - Follow up


The trial protocol has been published in Trials -